ASX:IMU

Imugene Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume12.70 million shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive IMU News and Ratings via Email

Sign-up to receive the latest news and ratings for Imugene and its competitors with MarketBeat's FREE daily newsletter.

About Imugene

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.

Why is the Imugene (ASX:IMU) share price lifting 7% today?
October 7, 2021 | msn.com

These were the best performing ASX biotech shares in September
October 4, 2021 | msn.com

Imugene (ASX:IMU) share price jumps 6% on Japanese patent news
September 22, 2021 | msn.com

Imugene granted HER-Vaxx immunotherapy patent in Japan
September 22, 2021 | proactiveinvestors.com

Top Biotech Stocks for Q4 2021
September 20, 2021 | finance.yahoo.com

Here’s why the Imugene (ASX:IMU) share price is up 6% so far this week
September 7, 2021 | fool.com.au

Imugene upgraded to Buy and target price boosted to 52 cents by Bell Porter on back of capital raise and new HER vaxx trials
September 3, 2021 | proactiveinvestors.com

Imugene reveals encouraging HER-Vaxx gastric cancer data, plans three new trials
September 1, 2021 | proactiveinvestors.com

Why the Imugene (ASX:IMU) share price is tumbling 7%
August 31, 2021 | msn.com

Imugene share price surges 7% as R&D efforts increase
August 30, 2021 | fool.com.au

See More Headlines

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:IMU
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.imugene.com
Phone: 61 3 9824 5254
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $7.23 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 3.75
Book Value: A$0.01 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.42
Current Ratio: 8.15
Quick Ratio: 8.11

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.99 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Imugene.

4.9 Community Rank

Outperform Votes
Imugene has received 29 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Imugene has received 10 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Imugene has received 74.36% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Imugene and other stocks. Vote “Outperform” if you believe IMU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMU will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Imugene does not currently pay a dividend.
Dividend Growth
Imugene does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Imugene insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Imugene (ASX:IMU) Frequently Asked Questions

What stocks does MarketBeat like better than Imugene?: Wall Street analysts have given Imugene a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Imugene wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
How were Imugene's earnings last quarter?: Imugene Limited (ASX:IMU) announced its quarterly earnings data on Thursday, February, 28th. The company reported $0.00 EPS for the quarter.
View Imugene's earnings history.
Who are Imugene's key executives?: Imugene's management team includes the following people:
Mr. Paul Edward-Alexander Hopper, Exec. Chairman (Age 65, Pay $137.4k)
Ms. Leslie Chong, CEO, MD & Exec. Director
Dr. Nicholas J. Ede, CTO & COO
Mr. Phillip Allen Hains, CFO & Joint Company Sec. (Age 62)
Dr. Rita Laeufle M.D., Ph.D., Chief Medical Officer
Dr. Monil Shah M.B.A., Pharm.D., Chief Bus. Officer
Mr. Justyn Peter Stedwell B.Com., B.Com, Joint Company Sec.
Who are some of Imugene's key competitors?: Some companies that are related to Imugene include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of IMU's competitors.
What other stocks do shareholders of Imugene own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Imugene investors own include Leap Therapeutics (LPTX), LightPath Technologies (LPTH), Jaguar Health (JAGX), Groupon (GRPN), Greenland Minerals (GGG), New Concept Energy (GBR), Fortescue Metals Group (FMG), Diffusion Pharmaceuticals (DFFN), Alumina (AWC) and Atossa Therapeutics (ATOS).
What is Imugene's stock symbol?: Imugene trades on the ASX under the ticker symbol "IMU."
How much money does Imugene make?: Imugene has a market capitalization of $0.00 and generates $7.23 million in revenue each year.
What is Imugene's official website?: The official website for Imugene is www.imugene.com.
How can I contact Imugene?: The company can be reached via phone at 61 3 9824 5254.

This page was last updated on 10/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.